Mutations in the human phosphofructokinase muscle subunit gene (PFKAM) are known to cause myopathy classified as glycogenosis type VII (Tarui disease). Previously described molecular defects include base substitutions altering encoded amino acids or resulting in abnormal splicing. We report a mutation resulting in phosphofructokinase deficiency in three patients from an Ashkenazi Jewish family. Using a reverse transcription PCR assay, PFKM subunit transcripts differing by length were detected in skeletal muscle tissue of all three affected subjects. In the longer transcript, an insertion of 252 nucleotides totally homologous to the structure of the 10th intron of the PFKM gene was found separating exon 10 from exon 11. In addition, two single base transitions were identified by direct sequencing: [exon 6; codon 95; CGA (Arg) to TGA (stop)] and [exon 7; codon 172; ACC (Thr) to ACT (Thr)] in either transcript. Singlestranded conformational polymorphism and restriction enzyme analyses confirmed the presence of these point substitutions in genomic DNA and strongly suggested homozygosity for the pathogenic allele. The nonsense mutation at codon 95 appeared solely responsible for the phenotype in these patients, further expanding genetic heterogeneity of Tarui disease. Transcripts with and without intron 10 arising from identical mutant alleles probably resulted from differential pre-mRNA processing and may represent a novel message from the PFKM gene.
Phosphofructokinase (PFK; ATP:D-fructose-6-phosphate 1-phosphotransferase, EC 2.7.1.11) plays a key regulatory role in one of mammals' most important metabolic routes: the glycolytic pathway (1) . The human enzyme is an -320-kDa protein composed of four subunits randomly associated to form functional tetramers. Three types of subunits, muscletype (M), liver-type (L), and platelet-type (P), are encoded by genes on chromosomes lq, 21q, and 10p, respectively (2) (3) (4) (5) . Variable expression of each locus in different tissues is known to reflect developmental and tissue-specific glycolytic requirements (6, 7) . Skeletal muscle and liver exclusively assemble M4 (muscle) and L4 (liver) homotetramers. Red blood cells and platelets, conversely, may harbor up to five isozymes by combining subunits in hybrid forms (8) . As a result, tissues with restricted subunit utilization are particularly vulnerable to mutations.
Muscle PFK deficiency (Tarui disease; glycogenosis type VII) is an inherited disorder characterized by exercise intolerance, cramps, and myoglobinuria with signs of hemolytic anemia and hyperuricemia (9, 10) . Partial PFK deficiency is routinely found in erythrocytes, but conclusive diagnosis of the infirmity requires biochemical assays in skeletal muscle (11) . The condition has been described in a number of Ashkenazi Jewish families as well as in non-Ashkenazi pedigrees of Japanese, Italian, Swiss, and French Canadian origins (12) (13) (14) (15) (16) (17) . Recent studies have led to the identification of 11 alleles associated with PFK deficiency (Table 1) .
We studied three patients from an Ashkenazi Jewish family of Polish origin having an inherited myopathy combined with recurrent compensated hemolysis. Metabolic block in the glycolytic pathway associated with reduced PFK activity and glycogen accumulation in skeletal muscle were (18) . Focal, mainly subsarcolemmal, glycogen deposits with proliferation of mitochondria containing paracrystalline inclusions were seen on electron microscopy (data not shown). After informed consent, blood and skeletal muscle specimens were collected for genetic evaluation.
Reverse Transcription (RT) and Sequencing. Total RNA from frozen muscle of patients and normal controls was extracted by centrifugation in cesium chloride (19) . For RT, 5 ,ug of total RNA from patients and 1 ,tg from controls were denatured at 70°C for 10 min in the presence of oligo(dT)-primers. Ten IThe sequence reported in this paper has been deposited in the GenBank data base (accession no. U24183).
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Conversion to double-stranded cDNA was achieved by PCR with 5' adaptor primers (Table 2 ) using 2 ,ul of the RT reaction as the starting template. Generated fragments encompassing -2.25 kb of the PFKM coding region were made cohesiveended by digestion with Not I and Xba I endonucleases and cloned into the Not I/Xba I site of pBluescript II Sk + /-phagemid (Stratagene). For sequencing, sequential Exo III deletions were performed, yielding partially overlapping subclones covering the transcripts. Both strands were sequenced using Prism cycle-sequencing protocol (Applied Biosyste,msPerkin-Elmer) and contigs assembled. The resulting cDNA sequences were aligned for comparative study with the human PFKM cDNA sequences retrieved from GenBank.
Genotyping. Patients and controls were screened for the point mutation in exon 6 using a modified version of a previously reported single-stranded confirmational polymorphism (SSCP)-PCR protocol (20) . PCR was performed in a 10-,tl volume, with 50 ng of genomic template, 1 ,tCi of [a-32P]dCTP (1 Ci = 37 GBq), and oligomers 6F and 6R (Table 2) . Reaction conditions were 30 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C. The amplification product was diluted 1:25 with 0.1% SDS/10 mM EDTA, and an aliquot mixed 1:1 with loading buffer, denatured at 95°C for 3 min, and chilled on ice before being loaded onto a 6% acrylamide/10% glycerol gel. Electrophoresis at 60 W for 5 h was followed by autoradiography (DuPont) at -70°C for 3 h. Testing for the transition in exon 7 was performed by restriction enzyme analysis. PCR-amplified exon 7 fragments were incubated with Nla IV (New England Biolabs) for 3 h at 37°C and resolved in a 3% agarose gel stained with ethidium bromide.
RESULTS
Four alternatively spliced PFKM transcripts have been previously characterized (21, 22 24 . In our study, RT-PCR with oligonucleotides 03F and 24R (Table  2 ) flanking the translated region on PFKM transcripts produced the expected -2.25-kb fragments in normal controls, while in each of the three patients two different species were observed measuring -2250 and -2500 nt (Fig. 2) . Sequence analysis of the transcripts revealed complete conservation of the normal exonic alignment except for an insertion of 252 nt interposed between exons 10 and 11 in the longer transcript.
Comparison of the insert with the GenBank sequences strongly suggested retention of the 10th intron. Since information on intronic sequences was limited to few nucleotides at exonintron boundaries, we determined the full structure of intron 10 by sequence analysis of genomic clones in control individuals. Total homology of the normal 10th intron with the insert in the patients' transcript sequences allowed identification of the 252-nt insert as the retained intron 10 (Fig. 3) . By RT-PCR Medical Sciences: Vasconcelos et al. amplification with lOF and 11R primers annealing at exons adjacent to intron 10, two different products were obtained in each of the patients: a 427-bp fragment retaining intron 10 and a 173-bp fragment without it (Fig. 4) . The same procedure failed to amplify the longer of these fragments when performed in normal controls. Additionally, to selectively amplify intron 10 from the patients' transcripts, RT-PCR assays were done with intF and intR primers annealing within intron 10 ( Table 2 ). An expected fragment averaging 220 bp was successfully produced from all affected, but not the control transcripts (Fig. 4) .
Two single-base transitions (both C -> T) were identified in longer and shorter RT-PCR fragments in all three patients.
One was a known silent polymorphism (12, 21) at position 516 in exon 7 [codon 172; ACC (Thr) to ACI (Thr)]. The other occurred at position 282 in exon 6, changing codon 95 from CGA (Arg) to TGA (stop) and thereby creating a premature translational termination signal. To confirm the genomic nature of this mutation, PCR amplification of exon 6 was carried out with resulting fragments cloned into plasmids. Ten recombinant clones from each patient were purified and sequenced. The codon 95 point substitution was present in a -3Kb _ -2Kb _ -lKb _ each sequenced clone, strongly suggesting homozygosity for the mutated allele. Use of the aberrant stop signal during cytoplasmic translation is predicted to produce severely truncated peptides having only 94 amino acids or 12% of the total sequence.
Since retention of intron 10 accounted for the unique difference between the isolated transcripts, there still was a possibility that these transcripts have originated from distinct alleles. In order to genotype patients and controls for the observed polymorphisms in exons 6 and 7, SSCP and restriction enzyme analysis were performed. For exon 6, the SSCP-PCR assay demonstrated a distinct profile of singlestranded fragment migration in patients compared to the controls and indicated homozygosity for the observed mutation (Fig. 5a ). Since the exon 7 substitution abolishes a Nla IV recognition site, restriction analysis was performed and indicated homozygosity for the ACI allele in all three patients, while all control alleles showed the more common ACC sequence (Fig. Sb) . The ACT allele frequency in the Ashkenazi Jewish population has been estimated at 0.092, based on the results of testing of 27 control individuals (54 alleles). 
DISCUSSION
This study presents a genetic analysis of three patients originating from an Ashkenazi Jewish family that segregates a congenital myopathy with compensated hemolysis and decreased PFK activity in muscle tissue. As the mode of inheritance of this disease remains unclear, we have carefully examined the data pertaining to the surveyed genealogy. The disease in this pedigree has classical features of autosomal recessive inheritance since the defective gene is located on an autosomal chromosome, and all patients originated from consanguineous marriages. The high inbreeding rate seen in this family (two consecutive consanguineous marriages) conferred to the pedigree a false impression of an autosomal dominant transmission pattern. The affected mother harbored two copies of the defective allele, greatly concentrating its frequency in the proband's generation.
The causal relationship between the characterized exon 6 CGA (Arg) to IGA (stop) mutation and the clinical phenotype in our patients is highly probable since (i) this mutation changes dramatically the predicted structure of the encoded protein, (ii) it was present in all tested transcripts, which is in agreement with the autosomal recessive pattern of inheritance, and (iii) this transition was not observed in wild-type alleles. This newly characterized defect represents a causative factor of Tarui m II -exon 6 mutation proved to be sensitive and may be satisfactory for standard population screening. However, lack of specificity requires that positive results are confirmed by sequence analysis. Retention of intron 10 in just one of the transcript species did not seem to bear any pathological role, as the aberrant translation stop signal was located upstream to the retained intron, presumably preventing its participation in protein coding. Most commonly, mutations causing splicing defects culminating with complete intron retention occur within highly conserved intronic sequences such as splice junction sites (24, 25) and less frequently in branch-point sites or in the polypyrimidine tract (26) , putatively disrupting important signaling sequences necessary for appropriate nuclear release of mature mRNA molecules. Point mutations and single base insertions into nonconserved intronic sequences also promote defective splicing, probably by altering the intron's secondary structure (27) . In our patients, sequence analysis of the unspliced intron and neighboring exons has failed to uncover any abnormality that could disturb the normal splicing mechanism. Alternatively, retention of intron 10 in some of the cytoplasmic mRNA species of the affected subjects could have resulted from differential pre-mRNA processing. This hypothesis seems more suitable because (i) retention of intron 10 did not occur in all PFKM subunit transcripts originating from homozygous loci and (ii) complete integrity of all signaling conserved intronic sequences was demonstrated. Among the mRNA types arising from the PFKM gene, type B, the predominant form expressed in skeletal muscle cells, has intron 2 retained in its 5' untranslated terminus (23) . Although PFKM transcripts retaining intron 10 have not yet been isolated from skeletal muscle of healthy individuals, it is possible that such species exist transiently in mature cells or during various stages of cell differentiation and could be overexpressed under pathological conditions. A Swedish patient with a base change in the last nucleotide of exon 13 and retention of part of intron 13 , and retention of intron 10 and part of intron 16 on the other allele was described in a recent review (28) .
The lack of PFK activity in individuals with glycogenosis type VII has been generically correlated with two basic mechanisms: (i) failure of M-subunit synthesis and (ii) synthesis of inactive proteins (29) . According to the first mechanism, lack of enzyme activity is linked to the failure of PFKM gene expression in muscle tissue. This situation is not applicable to our patients, since 33% of residual activity was found and two transcripts were well characterized in their skeletal muscle cells. By the second mechanism, defective PFKM-type subunits make the tetramers nonfunctional. Although the second mechanism seems to more closely resemble the situation, it probably does not explain the partial enzyme activity existent in muscle tissue of our patients. In reality, the residual activity encountered in our study continues to be unexplained since it did not seem to result from partial ability of truncated protein.
The termination codon identified in all three homozygous patients appeared to be linked to a decreased concentration of steady-state cytoplasmic mRNA. RT reaction with PFKM subunit transcripts in affected individuals required as much as five times the amount of total RNA template normally used in healthy controls. A similar phenomenon has been described in other human disorders including cystic fibrosis (30) . The reasons why nonsense and frame-shift mutations may induce intranuclear transcript instability are not clear. Several parameters such as the transcription rate, the efficiency of premRNA processing and transport into cytoplasm, and the stability of the produced mature mRNA are thought to be individually or simultaneously affected (31) . Moreover, if ribosomal translation of these defective transcripts occurs in our patients, it is predicted to produce severely truncated PFKM subunits consisting of only "12% of the normal amino acid content. Even if random tetramerization of such pathologically shortened motifs takes place, it is very unlikely that the assembled protein would carry catalytic properties since the active sites and regulatory centers would be absent.
Various factors may contribute to the complexity of clinical expression: developmental mosaic formation, multiple chromosomal loci interaction, environmental influences, and particularly tissue-specific alternative splicing. In other human disorders where stop codons were similarly found as the underlying defect (32), some level of "phenotypic rescue" attributed to increased nuclear release of mature mRNA species skipping the exon harboring the mutation is believed to occur. In our patients, successful removal of the mutated exon 6 has not been observed in the isolated transcripts. In fact, even if exon 6 had been skipped, no degree of "rescue" would have been achieved because the resultant coding frame would have shifted, leading to a premature termination of translation within exon 7, thereby preventing a "functional protein" from being synthesized. To the contrary, complete retention of intron 10 had happened in one of the identified transcripts. However, rather than a proper rescue attempt, the retention appeared primarily related to an overexpression of an unknown PFKM gene message in skeletal muscle. It is anticipated that future efforts will elucidate these and other important points and improve our understanding of the molecular dynamics of this debilitating disorder.
